Email Us
Call Us
AUSTIN, Texas – December 12, 2011 – Altogen in vivo delivery technology appears among the published citations for one of the most widely referenced papers in the field of central nervous system nucleic acid delivery, published in Nature Biotechnology. The 2011 study demonstrated systemic delivery of siRNA to mouse brain tissue using targeted exosomes, work that helped establish the feasibility of crossing the blood-brain barrier with therapeutic oligonucleotides and has shaped a decade of CNS delivery research since. Independent investigators working at that level select reagents on performance, not on marketing, and the appearance of Altogen delivery products in that literature reflects the technical standard the platform is held to.
Development of novel delivery technology underpins Altogen Labs’ in vivo RNAi and tissue-targeted delivery services. Sponsors developing oligonucleotide therapeutics, gene therapies, and CNS-directed programs can access an end-to-end workflow at Altogen Labs: oligonucleotide design and chemical modification, in vitro validation, microfluidics-based liposome and nanoparticle encapsulation, in vivo tissue-targeted delivery in rodents, and confirmation of knockdown by TaqMan oligonucleotide accumulation assays, target mRNA quantification by RT-PCR, and protein-level analysis by automated Western blot and ELISA.
Delivery has been functionally validated across brain, heart, lung, liver, pancreas, kidney, spleen, and multiple tumor types, in BALB/c, nude, and NOD/SCID mice and Sprague Dawley rats, using systemic tail vein administration and direct intratumoral injection. Altogen Labs pairs this delivery capability with its validated tumor model collection, allowing a delivery study and an efficacy study to be run in the same model, in the same facility, under the same protocol – eliminating the cross-laboratory variability that frequently confounds gene therapy programs.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, offering a large collection of in-house validated xenograft models and extensive experience in efficacy xenograft studies and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Alvarez-Erviti L, et al., “Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes,” Nature Biotechnology, 2011;29(4):341–345